Analyst Price Targets — TNYA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 2:37 pm | Mani Foroohar | Leerink Partners | $2.00 | $0.95 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "remains on track to share interim data" |
| January 8, 2026 12:44 pm | — | Morgan Stanley | $2.00 | $0.80 | TheFly | Tenaya Therapeutics price target lowered to $2 from $5 at Morgan Stanley |
| December 12, 2025 1:47 pm | — | H.C. Wainwright | $3.00 | $0.88 | TheFly | Tenaya Therapeutics price target lowered to $3 from $5 at H.C. Wainwright |
Latest News for TNYA
Belite Bio (NASDAQ: BLTE - Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Analyst Ratings This is a summary of current
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026
Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) shares are up on Thursday, reflecting a positive market response to a research collaboration agreement with Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY).
Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TNYA.
U.S. House Trading
No House trades found for TNYA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.